The PE Ratio as of November 2024 (TTM) for Supernus Pharmaceuticals, Inc. (SUPN) is 385.56

According to Supernus Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is 385.56. This represents a change of -61.78% compared to the average of 1.01K of the last 4 quarters.

Supernus Pharmaceuticals, Inc. (SUPN) Historical PE Ratio (quarterly & annually)

How has SUPN PE Ratio performed in the past?

The mean historical PE Ratio of Supernus Pharmaceuticals, Inc. over the last ten years is 140.90. The current 385.56 PE Ratio has changed 27.26% with respect to the historical average. Over the past ten years (40 quarters), SUPN's PE Ratio was at its highest in in the March 2024 quarter at 3.70K. The PE Ratio was at its lowest in in the June 2023 quarter at -492.89.

Supernus Pharmaceuticals, Inc. (SUPN) PE Ratio by Quarter and Year

Discovering the peaks and valleys of Supernus Pharmaceuticals, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Supernus Pharmaceuticals, Inc. (SUPN) Average PE Ratio

How has SUPN PE Ratio performed in the past?

The current PE Ratio of Supernus Pharmaceuticals, Inc. (SUPN) is less than than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Supernus Pharmaceuticals, Inc. (SUPN) PE Ratio vs. Peers

How is SUPN’s PE Ratio compared to its peers?

Supernus Pharmaceuticals, Inc.’s PE Ratio is greater than Prestige Consumer Healthcare Inc. (17.95), greater than Evotec SE (-4.20), greater than Collegium Pharmaceutical, Inc. (10.62), greater than Deciphera Pharmaceuticals, Inc. (-11.74), greater than Eagle Pharmaceuticals, Inc. (0.27), greater than ANI Pharmaceuticals, Inc. (40.06), greater than Phibro Animal Health Corporation (372.68), greater than Pacira BioSciences, Inc. (11.94), greater than Dr. Reddy's Laboratories Limited (18.68), greater than Silver Spike Investment Corp. (13.39), greater than Regencell Bioscience Holdings Limited (-21.65),

Build a custom stock screener for Supernus Pharmaceuticals, Inc. (SUPN) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Supernus Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Supernus Pharmaceuticals, Inc. (SUPN) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Supernus Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.